Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Webcast of Annual Meeting

BUFFALO, NY--(Marketwired - Apr 4, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its...
March 16, 2016 14:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure

BUFFALO, NY--(Marketwired - Mar 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an update on the regulatory review of its pre-Emergency Use Authorization (pre-EUA) submission for...
February 22, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports 2015 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Feb 22, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2015....
February 09, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute

BUFFALO, NY--(Marketwired - Feb 9, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic...
February 02, 2016 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation

BUFFALO, NY--(Marketwired - Feb 2, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the...
January 26, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation

BUFFALO, NY--(Marketwired - Jan 26, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as...
January 21, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure

BUFFALO, NY--(Marketwired - Jan 21, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for...
December 22, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Rusnano Make Additional Investments in Panacela

BUFFALO, NY--(Marketwired - Dec 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO...
December 14, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute

BUFFALO, NY--(Marketwired - Dec 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in...
November 30, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod

BUFFALO, NY--(Marketwired - Nov 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide...